Eli Lilly reported Phase 2 results showing its amylin receptor agonist eloralintide drove mean weight losses up to about 20% at 48 weeks and produced fewer gastrointestinal side effects than comparators, prompting the company to advance the candidate into Phase 3. Lilly presented the data at ObesityWeek and positioned eloralintide as a potential second‑generation obesity therapy. The dataset included dose‑dependent responses across multiple cohorts with the highest dose producing the largest mean weight declines. Lilly emphasized tolerability and dose‑escalation strategies that reduced GI events compared with prior amylin programs. The results sharpen competition in the obesity space as rivals including Novo Nordisk and other amylin and GLP‑1 developers prepare late‑stage programs. Investors and payors will watch efficacy, safety, and commercial positioning as second‑generation agents enter registrational testing.